Filovirus Neutralising Antibodies: Mechanisms of Action and Therapeutic Application

Overview

Journal Pathogens

Date 2021 Sep 28

PMID 34578233

Citations 9

Authors

Alexander Hargreaves

Caolann Brady

Jack Mellors

Tom Tipton

Miles W Carroll

Stephanie Longet

Affiliations

Soon will be listed here.

Abstract

Filoviruses, especially Ebola virus, cause sporadic outbreaks of viral haemorrhagic fever with very high case fatality rates in Africa. The 2013-2016 Ebola epidemic in West Africa provided large survivor cohorts spurring a large number of human studies which showed that specific neutralising antibodies played a key role in protection following a natural Ebola virus infection, as part of the overall humoral response and in conjunction with the cellular adaptive response. This review will discuss the studies in survivors and animal models which described protective neutralising antibody response. Their mechanisms of action will be detailed. Furthermore, the importance of neutralising antibodies in antibody-based therapeutics and in vaccine-induced responses will be explained, as well as the strategies to avoid immune escape from neutralising antibodies. Understanding the neutralising antibody response in the context of filoviruses is crucial to furthering our understanding of virus structure and function, in addition to improving current vaccines & antibody-based therapeutics.

Citing Articles

Rational design of next-generation filovirus vaccines with glycoprotein stabilization, nanoparticle display, and glycan modification.

Lee Y, Zhang Y, Newby M, Ward G, Gomes K, Auclair S bioRxiv. 2025; .

PMID: 40060701 PMC: 11888476. DOI: 10.1101/2025.03.02.641072.

Quantification of Neutralizing Antibodies in Serum Using VSV-MARV-GFP.

Fletcher P Methods Mol Biol. 2024; 2877:355-360.

PMID: 39585633 DOI: 10.1007/978-1-0716-4256-6_24.

Antibodies targeting the glycan cap of Ebola virus glycoprotein are potent inducers of the complement system.

Ilinykh P, Huang K, Gunn B, Kuzmina N, Kedarinath K, Jurado-Cobena E Commun Biol. 2024; 7(1):871.

PMID: 39020082 PMC: 11255267. DOI: 10.1038/s42003-024-06556-0.

Novel antiviral approaches for Marburg: a promising therapeutics in the pipeline.

Srivastava S, Kumar S, Ashique S, Sridhar S, Shareef J, Thomas S Front Microbiol. 2024; 15:1387628.

PMID: 38725678 PMC: 11079314. DOI: 10.3389/fmicb.2024.1387628.

Emerging roles of the Protein Phosphatase 1 (PP1) in the context of viral infections.

Corda P, Bollen M, Ribeiro D, Fardilha M Cell Commun Signal. 2024; 22(1):65.

PMID: 38267954 PMC: 10807198. DOI: 10.1186/s12964-023-01468-8.

References

Pollard A, Launay O, Lelievre J, Lacabaratz C, Grande S, Goldstein N . Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2020; 21(4):493-506. DOI: 10.1016/S1473-3099(20)30476-X. View

Janus B, van Dyk N, Zhao X, Howell K, Soto C, Aman M . Structural basis for broad neutralization of ebolaviruses by an antibody targeting the glycoprotein fusion loop. Nat Commun. 2018; 9(1):3934. PMC: 6158212. DOI: 10.1038/s41467-018-06113-4. View

Mire C, Geisbert J, Borisevich V, Fenton K, Agans K, Flyak A . Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody. Sci Transl Med. 2017; 9(384). PMC: 5719873. DOI: 10.1126/scitranslmed.aai8711. View

Qiu X, Fernando L, Alimonti J, Melito P, Feldmann F, Dick D . Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses. PLoS One. 2009; 4(5):e5547. PMC: 2678264. DOI: 10.1371/journal.pone.0005547. View

Miller E, Obernosterer G, Raaben M, Herbert A, Deffieu M, Krishnan A . Ebola virus entry requires the host-programmed recognition of an intracellular receptor. EMBO J. 2012; 31(8):1947-60. PMC: 3343336. DOI: 10.1038/emboj.2012.53. View

Steeds K, Hall Y, Slack G, Longet S, Strecker T, Fehling S . Pseudotyping of VSV with Ebola virus glycoprotein is superior to HIV-1 for the assessment of neutralising antibodies. Sci Rep. 2020; 10(1):14289. PMC: 7459353. DOI: 10.1038/s41598-020-71225-1. View

Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi J . Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Elife. 2020; 9. PMC: 7723407. DOI: 10.7554/eLife.61312. View

Tipton T, Hall Y, Bore J, White A, Sibley L, Sarfas C . Characterisation of the T-cell response to Ebola virus glycoprotein amongst survivors of the 2013-16 West Africa epidemic. Nat Commun. 2021; 12(1):1153. PMC: 7895930. DOI: 10.1038/s41467-021-21411-0. View

Geisbert T, Daddario-DiCaprio K, Geisbert J, Reed D, Feldmann F, Grolla A . Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine. 2008; 26(52):6894-900. PMC: 3398796. DOI: 10.1016/j.vaccine.2008.09.082. View

10.

Olejnik J, Ryabchikova E, Corley R, Muhlberger E . Intracellular events and cell fate in filovirus infection. Viruses. 2011; 3(8):1501-31. PMC: 3172725. DOI: 10.3390/v3081501. View

11.

Yu D, Weng T, Shen L, Wu X, Hu C, Wang F . Development and Characterization of Neutralizing Antibodies Against Zaire Ebolavirus Glycoprotein and Protein 40. Cell Physiol Biochem. 2018; 50(3):1055-1067. DOI: 10.1159/000494530. View

12.

Hiatt A, Zeitlin L, Whaley K . Multiantibody strategies for HIV. Clin Dev Immunol. 2013; 2013:632893. PMC: 3690221. DOI: 10.1155/2013/632893. View

13.

de Arellano E, Sanchez-Lockhart M, Perteguer M, Bartlett M, Ortiz M, Campioli P . First Evidence of Antibodies Against Lloviu Virus in Schreiber's Bent-Winged Insectivorous Bats Demonstrate a Wide Circulation of the Virus in Spain. Viruses. 2019; 11(4). PMC: 6521100. DOI: 10.3390/v11040360. View

14.

Mire C, Geisbert J, Agans K, Satterfield B, Versteeg K, Fritz E . Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primates. PLoS One. 2014; 9(4):e94355. PMC: 3997383. DOI: 10.1371/journal.pone.0094355. View

15.

Murin C, Wilson I, Ward A . Antibody responses to viral infections: a structural perspective across three different enveloped viruses. Nat Microbiol. 2019; 4(5):734-747. PMC: 6818971. DOI: 10.1038/s41564-019-0392-y. View

16.

Olejnik J, Hume A, Leung D, Amarasinghe G, Basler C, Muhlberger E . Filovirus Strategies to Escape Antiviral Responses. Curr Top Microbiol Immunol. 2017; 411:293-322. PMC: 5973841. DOI: 10.1007/82_2017_13. View

17.

Khurana S, Ravichandran S, Hahn M, Coyle E, Stonier S, Zak S . Longitudinal Human Antibody Repertoire against Complete Viral Proteome from Ebola Virus Survivor Reveals Protective Sites for Vaccine Design. Cell Host Microbe. 2020; 27(2):262-276.e4. PMC: 7071344. DOI: 10.1016/j.chom.2020.01.001. View

18.

Kemenesi G, Kurucz K, Dallos B, Zana B, Foldes F, Boldogh S . Re-emergence of Lloviu virus in Miniopterus schreibersii bats, Hungary, 2016. Emerg Microbes Infect. 2018; 7(1):66. PMC: 5906664. DOI: 10.1038/s41426-018-0067-4. View

19.

Gilchuk P, Kuzmina N, Ilinykh P, Huang K, Gunn B, Bryan A . Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein. Immunity. 2018; 49(2):363-374.e10. PMC: 6104738. DOI: 10.1016/j.immuni.2018.06.018. View

20.

Zampieri C, Sullivan N, Nabel G . Immunopathology of highly virulent pathogens: insights from Ebola virus. Nat Immunol. 2007; 8(11):1159-64. PMC: 7097212. DOI: 10.1038/ni1519. View